133 related articles for article (PubMed ID: 28682808)
1. Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome.
Badimon L; Padró T; Cubedo J
Curr Opin Lipidol; 2017 Oct; 28(5):427-433. PubMed ID: 28682808
[TBL] [Abstract][Full Text] [Related]
2. Predicting cardiovascular disease in familial hypercholesterolemia.
Paquette M; Baass A
Curr Opin Lipidol; 2018 Aug; 29(4):299-306. PubMed ID: 29708923
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?
Mata P; Alonso R; Pérez de Isla L
Curr Opin Lipidol; 2018 Dec; 29(6):445-452. PubMed ID: 30382952
[TBL] [Abstract][Full Text] [Related]
4. [Familial hypercholesterolemia].
Windler E; Beil FU; Altenburg C; Rinninger F
Dtsch Med Wochenschr; 2012 Nov; 137(46):2375-9. PubMed ID: 23132157
[TBL] [Abstract][Full Text] [Related]
5. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.
Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A
J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129
[TBL] [Abstract][Full Text] [Related]
6. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.
Ooi EM; Barrett PH; Watts GF
Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036
[TBL] [Abstract][Full Text] [Related]
7. Identifying familial hypercholesterolemia in acute coronary syndrome.
Gencer B; Nanchen D
Curr Opin Lipidol; 2016 Aug; 27(4):375-81. PubMed ID: 27092769
[TBL] [Abstract][Full Text] [Related]
8. Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia.
Martinez LR; Santos RD; Miname MH; Deus DF; Lima ES; Maranhão RC
Metabolism; 2013 Aug; 62(8):1061-4. PubMed ID: 23540443
[TBL] [Abstract][Full Text] [Related]
9. Reverse cholesterol transport in familial hypercholesterolemia.
Guerin M
Curr Opin Lipidol; 2012 Aug; 23(4):377-85. PubMed ID: 22510809
[TBL] [Abstract][Full Text] [Related]
10. Predictors of cardiovascular risk in familial hypercholesterolemia.
Romero-Jiménez MJ; Mansilla-Rodríguez ME; Gutiérrez-Cortizo EN
Curr Opin Lipidol; 2023 Dec; 34(6):272-277. PubMed ID: 37769168
[TBL] [Abstract][Full Text] [Related]
11. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
Thiery J; Burkhardt R
Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
[TBL] [Abstract][Full Text] [Related]
12. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia.
Ogura M; Hori M; Harada-Shiba M
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):181-8. PubMed ID: 26543100
[TBL] [Abstract][Full Text] [Related]
13. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
[TBL] [Abstract][Full Text] [Related]
15. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia.
Paquette M; Chong M; Thériault S; Dufour R; Paré G; Baass A
J Clin Lipidol; 2017; 11(3):725-732.e5. PubMed ID: 28456682
[TBL] [Abstract][Full Text] [Related]
16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
19. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
[TBL] [Abstract][Full Text] [Related]
20. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
